Jean-François Dufour, UEG 2021: Treatment Pipeline for NASH
It was a pleasure to speak with Prof. Jean-François Dufour (University of Bern, Bern, Switzerland) about drug development in non-alcoholic steatohepatitis (NASH) and in particular the farnesoid X receptor (FXR) as a therapeutic target. His presentation entitled ‘Treatment of NASH: What is in the pipeline?’ was given at UEG week, 2-5 Oct 2021. Questions What […]
Journal articles and more to your inbox
Get the latest clinical insights from touchENDOCRINOLOGYSign me up!